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Objectives The aim of this study was to investigate the influence of rate control on quality of life (QOL).
Background The RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) trial showed that lenient rate control is not
inferior to strict rate control in terms of cardiovascular morbidity and mortality. The influence of stringency of
rate control on QOL is unknown.
Methods In RACE II, a total of 614 patients with permanent atrial fibrillation (AF) were randomized to lenient (resting
heart rate [HR] 110 beats/min) or strict (resting HR 80 beats/min, HR during moderate exercise 110
beats/min) rate control. QOL was assessed in 437 patients using the Medical Outcomes Study 36-item Short-
Form Health Survey (SF-36) questionnaire, AF severity scale, and Multidimensional Fatigue Inventory-20
(MFI-20) at baseline, 1 year, and end of study. QOL changes were related to patient characteristics.
Results Median follow-up was 3 years. Mean age was 68  8 years, and 66% were males. At the end of follow-up, all
SF-36 subscales were comparable between both groups. The AF severity scale was similar at baseline and end
of study. At baseline and at end of study there were no differences in the MFI-20 subscales between the 2
groups. Symptoms at baseline, younger age, and less severe underlying disease, rather than assigned therapy or
heart rate, were associated with QOL improvements. Female sex and cardiovascular endpoints during the study
were associated with worsening of QOL.
Conclusions Stringency of heart rate control does not influence QOL. Instead, symptoms, sex, age, and severity of the under-
lying disease influence QOL. (Rate Control Efficacy in Permanent Atrial Fibrillation; NCT00392613) (J Am Coll
Cardiol 2011;58:1795–803) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.06.055Atrial fibrillation (AF) causes symptoms such as palpita-
tions, dyspnea, and fatigue (1,2). Quality of life (QOL) is
reduced in patients with AF compared with healthy subjects
(3,4). Restoration and maintenance of sinus rhythm im-
prove QOL (4–7), but sinus rhythm can be maintained in a
minority of patients (8–10). The AFFIRM (Atrial Fibril-
lation Follow-up Investigation of Rhythm Management)
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ment in cardiovascular morbidity and mortality and QOL
during a rhythm control strategy (8,9). Therefore, rate
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Quality of Life in Permanent Atrial Fibrillation October 18, 2011:1795–803control has become first-choice
therapy in elderly patients with-
out severe symptoms. The optimal
level of heart rate control, how-
ever, was unknown. Recently, the
RACE II (Rate Control Efficacy
in Permanent Atrial Fibrillation:
A Comparison Between Lenient
and Strict Rate Control II) trial
revealed that lenient rate control
is as effective as strict rate control
with respect to morbidity and mortality (11,12). Strict rate
control may improve QOL due to a reduction of the heart
rate. However, more negative dromotropic drugs and higher
doses may reduce this positive effect on QOL.
We hypothesized that QOL is comparable between
lenient and strict rate control. The aim of this predefined
substudy of the RACE II trial was to assess the effect of
stringency of heart rate control on QOL measured with
general health, AF-specific, and fatigue questionnaires (13).
In addition, we investigated patient characteristics associ-
ated with a low QOL at baseline and changes in QOL
during follow-up.
Methods
Patient population. This study was performed in patients
with permanent AF included in the RACE II study (11,13).
The institutional review board of each participating hospital
approved the study, and all patients provided written in-
formed consent. We included 614 patients who were
randomized to lenient rate control (resting heart rate 110
beats/min) or strict rate control (resting heart rate 80
beats/min and heart rate 110 beats/min during moderate
exercise). Rate control was instituted with beta-blockers,
nondihydropyridine calcium-channel blockers, and digoxin,
alone or in combination and at various doses, until the target
heart rate was achieved (13). Drug use at the end of the
dose-adjustment phase was used as baseline medication in
the present analysis. The primary outcome in the main study
was a composite of cardiovascular death, hospitalization for
heart failure, stroke, systemic embolism, major bleeding, or
arrhythmic events, including syncope, sustained ventricular
tachycardia, cardiac arrest, life-threatening adverse effects of rate
control drugs, and pacemaker or cardioverter-defibrillator
implantation. The arrhythmic events were analyzed for the
purpose of the present substudy as the occurrence of any
composite arrhythmic endpoint. Both strategies were asso-
ciated with a comparable rate of cardiovascular adverse
events. Patients were excluded from the present analyses when
they did not complete one of the QOL questionnaires during
follow-up (64 patients in the lenient control group and 78
patients in the strict control arm). Patients who died during
the study were also not included in the analysis (17 patients
in the lenient control group and 18 in the strict control
Abbreviations
and Acronyms
AF  atrial fibrillation
IQR  interquartile range
MFI-20  Multidimensional
Fatigue Inventory-20
QOL  quality of life
SF-36  36-item
Short-Form Health Surveygroup). Minimum follow-up was 2 years, and maximal tfollow-up was 3 years. Median follow-up was 3 years
(interquartile range [IQR]: 2.2 to 3.1 years). Results of the
questionnaires at baseline, 12 months, and end of study are
presented. Importantly, the 12 months of follow-up were
the first measurement of QOL after the dose-adjustment
phase.
Baseline characteristics were comparable between the
excluded patients and included patients. Baseline character-
istics of the included patients are shown in Table 1. With
the exception of a higher prevalence of coronary artery
disease and use of statins in the lenient control group,
baseline characteristics were comparable between groups.
After the dose-adjustment phase, 98% of the patients in the
lenient control group met the heart rate target versus 76% in
the strict control group. Patients randomized to strict rate
control used more and higher dosages of negative dromo-
tropic drugs compared with the rate in the lenient control
group (Table 1). During the total follow-up, heart rate was
significantly higher in the lenient control group compared
with the strict control group (after dose adjustment 93 
beats/min vs. 76  11 beats/min; at 1 year 84  13
eats/min vs. 74  12 beats/min; at end of study 84  14
eats/min vs. 75  14 beats/min [all p  0.05]).
OL questionnaires. General health–related QOL was
easured by using the Medical Outcomes Study 36-item
hort-Form Health Survey (SF-36).
The SF-36 is a standardized, validated, general health
urvey that has been used frequently in arrhythmia studies
14). The SF-36 has been translated and validated in the
etherlands (15). It contains items to assess physical health
general health perception, physical functioning, and role
imitations due to physical problems and bodily pain) and
ental health (social functioning, role limitations due to
motional problems, mental health, and vitality). The items
or general health perception and vitality assess both phys-
cal and mental health. Each scale is composed of a number
f multiple choice questions. For each of the 8 subscales,
cores are transformed to a scale ranging from 0 to 100, with
ower scores representing lower QOL.
Severity of AF-related symptoms was assessed using the
niversity of Toronto AF Severity Scale (AF severity scale)
3,16,17), a disease-specific instrument intended to measure
he patient’s perception of severity of arrhythmia-related
ymptoms. This 7-item questionnaire includes common AF
ymptoms (e.g., palpitations, dyspnea). Items are rated on a
-point scale. Scores range from 0 to 35, with higher scores
ndicating greater AF symptom severity.
Severity of fatigue was measured using the Multidimen-
ional Fatigue Inventory-20 (MFI-20) (18,19). The
FI-20 is a self-report instrument containing 20 state-
ents covering different aspects of fatigue. The 20 items are
rganized in 5 scales: general, physical and mental fatigue,
nd reduced activity and motivation. Scores range from 4 to
0, with the scales balanced to reduce influence of response
endencies.
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October 18, 2011:1795–803 Quality of Life in Permanent Atrial FibrillationBaseline CharacteristicsTable 1 Baseline Characteristics
Characteristic
Lenient Rate Control
(n  230)
Strict Rate Control
(n  207)
Total Population
(N  437)
Age (yrs) 69 7 68 8 68 8
Male 157 (68.3) 133 (64.3) 290 (66.4)
Total atrial fibrillation duration (months) 17 (6–54) 19 (6–58) 18 (6–58)
Duration permanent atrial fibrillation (months) 3 (1–6) 3 (1–5) 3 (1–6)
Heart rate in rest (beats/min) 95 14 95 11 95 12
Hypertension 144 (62.6) 120 (58.0) 264 (60.4)
Coronary artery disease 53 (23.0) 30 (14.5)* 83 (19.0)
Valvular heart disease 44 (19.1) 45 (21.7) 89 (20.4)
Chronic obstructive pulmonary disease 25 (11.6) 26 (14.2) 51 (12.9)
Diabetes mellitus 21 (9.1) 19 (9.2) 40 (9.2)
Lone atrial fibrillation† 5 (2.2) 6 (2.9) 11 (2.5)
Previous heart failure hospitalization 19 (8.3) 18 (8.7) 37 (8.5)
CHADS2 score‡ 1.3 1.0 1.3 1.1 1.3 1.0
0 or 1 143 (62.2) 139 (67.2) 282 (64.5)
2 64 (27.8) 43 (20.8) 107 (24.5)
3–6 23 (10.0) 25 (12.1) 48 (11.0)
Symptoms 127 (61.4) 127 (55.2) 254 (58.1)
Palpitations 47 (20.4) 59 (28.5)* 106 (24.3)
Dyspnea 77 (33.5) 84 (40.6) 161 (36.8)
Fatigue 65 (28.3) 69 (33.3) 134 (30.7)
New York Heart Association functional class
I 153 (66.5) 124 (64.0) 277 (65.1)
II 64 (27.8) 75 (36.32) 139 (31.8)
III 13 (5.7) 8 (3.9) 21 (4.8)
Echocardiographic parameters (mm)
Left atrial size, long-axis 46 7 46 7 46 7
Left ventricular end-diastolic diameter 51 7 51 7 51 7
Left ventricular end-systolic diameter 36 8 36 9 36 8
Left ventricular ejection fraction 52 11 53 12 53 11
40% 28 (12.2) 32 (15.5) 60 (13.7)
Heart rate distribution at the end of the dose
adjustment phase (beats/min)
70 1 (0.4) 45 (21.7) 46 (22.2)
70–80 4 (1.8) 119 (57.5) 123 (59.2)
81–90 81 (35.2) 24 (11.6) 105 (46.8)
91–100 93 (40.4) 11 (5.3) 104 (45.7)
100 51 (22.2) 8 (3.9) 59 (26.0)
Rate control medications used at the end of the
dose-adjustment phase
No rate control drugs 24 (10.4) 2 (1.0) 26 (6.0)
Beta-blocker alone 99 (43.0) 46 (22.2) 145 (33.2)
Verapamil/diltiazem alone or digoxin 13 (5.7)/18 (7.8) 11 (5.3)/1 (0.5) 24 (5.5)/19 (4.4)
Beta-blocker  verapamil/diltiazem or digoxin 7 (3.0)/45 (19.6) 25 (12.1)/79 (38.2) 32 (7.3)/124 (28.4)
Verapamil/diltiazem  digoxin 13 (5.7) 24 (11.6) 37 (8.5)
Beta-blocker  verapamil/diltiazem  digoxin 1 (0.4) 14 (6.8) 15 (3.4)
Sotalol or amiodarone 10 (4.4) 5 (2.4) 15 (3.4)
Dose (mg) (no. of patients)
Beta-blocker (normalized to metoprolol-
equivalent doses)
119 81 (153) 169 87 (166) 145 88 (319)
Verapamil 183 56 (30) 221 102 (69) 209 92 (99)
Diltiazem 230 87 (4) 233 52 (6) 232 63 (10)
Digoxin 0.19 0.8 (82) 0.21 0.9 (120) 197 83 (202)
Other medications in use at the end of the
dose-adjustment phase
ARB or ACE inhibitor 122 (53.0) 100 (48.3) 222 (50.8)
Diuretic 98 (42.6) 81 (39.1) 179 (41.0)
Statin§ 82 (35.7) 51 (24.6)* 133 (30.4)
Vitamin K antagonist 228 (99.1) 203 (98.1) 431 (98.6)
Aspirin 2 (0.9) 4 (1.9) 6 (1.4)
Values are expressed as mean  SD or n (%). *p  0.05 compared with lenient rate control. †Defined as atrial fibrillation in the absence of
cardiovascular disease and extracardiac precipitating causes of atrial fibrillation. ‡A measure of the risk of stroke in patients with atrial fibrillation, with
scores ranging from 0 to 6, with higher scores indicating a greater risk. Congestive heart failure, hypertension, age75 years, and diabetes mellitus are
each assigned1point and previous stroke or transient ischemic attack is assigned2points; the score is calculated by summing all points for a given patient.
§Statins were defined as 3-hydroxy-3-methylglutaryl-coenzym A reductase inhibitors.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker.
s
(
1798 Groenveld et al. JACC Vol. 58, No. 17, 2011
Quality of Life in Permanent Atrial Fibrillation October 18, 2011:1795–803Statistical analysis. To analyze patient characteristics as-
ociated with low QOL at baseline, patients with low scores
scores lower than the mean value 1 SD) were identified.
To assess relevant changes over time in SF-36 subscales, the
changes over time were divided into relevant and irrelevant.
A relevant change was pre-defined for each SF-36 subscale.
The relevant change was based on the number of steps the
patient improved or worsened on the stepwise multiple
choice questions that comprised each SF-36 subscale be-
tween baseline and end of study (4). The following changes
in individual patients were regarded as relevant: 1 step for
role limitation due to physical problems and role limitations
due to emotional problems, 2 steps for social functioning
and bodily pain, and 3 steps for general health perception,
physical functioning, mental health, and vitality. Based on
the aforementioned definition of relevant changes in the
SF-36 subscales, the relevant effect size of each SF-36
subscale was defined as 0.58 SD or higher from baseline
(20). Also, for the AF severity scale and the MFI-20, a
relevant change was defined as an effect size of0.58 SD in
these questionnaires. This is in accordance with the litera-
ture, which defines an effect size between 0.50 and 0.80 SD
as a moderate change (20).
Clinical correlates of change in QOL, including clinical
baseline and follow-up characteristics, were determined.
The use of beta-blockers was included in this analysis
because these agents effectively reduce heart rate but may
reduce exercise capacity and induce fatigue (21). Use of
other negative dromotropic drugs or a combination of
negative dromotropic drugs and dosages were not included
in this analysis because randomization strategy was our
variable of interest, not different types or combinations of
negative dromotropic drugs. Furthermore, because of the
high number of possible combinations of negative dromo-
Figure 1 Percentage of Patients With Any Symptom
Symptoms of atrial fibrillation during the study, displayed by randomization strategtropic drugs and dosages, this would inappropriately com-
plicate the analysis.
To examine changes over time for each QOL question-
naire and subsequent subscale, the method of repeated
measures was performed. For comparison of scores between
groups, a general linear model and the Student t test for
independent variables was used. Variables with a non-
normal distribution were tested with the Mann-Whitney
and the Wilcoxon tests. Correlation between heart rate and
QOL was assessed using the Pearson correlation. The
univariate chi-square test and Student t test for independent
variables, followed by multivariate stepwise logistic regres-
sion analyses, were performed to determine predictors of
relevant QOL change over follow-up. Baseline characteris-
tics, high baseline heart rate (100 beats/min) in combi-
nation with a relevant (20% heart rate reduction), occur-
rence of a primary endpoint, and symptoms during the study
were univariately tested in a logistic regression model. All
univariate predictors with p  0.1 were tested in a multi-
variate logistic regression model using a stepwise approach.
In the multivariate model, a variable was excluded when p
0.05. In all analyses, a value of p  0.05 was considered
statistically significant. All analyses were performed on an
intention-to-treat basis.
Results
Symptoms of AF during the study. At baseline, 58% of
patients experienced symptoms of AF, predominantly dys-
pnea, fatigue, and palpitations (Table 1). At end of study,
48% of patients experienced symptoms of AF (dyspnea in
139 [32%], fatigue in 110 [25%], and palpitations in 49
[11%] patients). There were no differences in symptoms of
AF at either baseline or at end of study between the lenient
and strict control groups (Fig. 1).
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October 18, 2011:1795–803 Quality of Life in Permanent Atrial FibrillationQOL at baseline. At study entry, SF-36 scales were
comparable between the lenient and strict control groups
(Table 2). Low SF-36 subscales scores (scores below the
mean value 1 SD) at baseline were associated with the
resence of symptoms (all SF-36 subscales), diabetes mel-
itus (subscale general health), and female sex (subscales
hysical functioning, physical role limitation, bodily pain,
ocial functioning, and vitality). At baseline, no significant
ifferences between the lenient (6 [IQR: 3 to 11]) and strict
7 [IQR: 3 to 12]) control groups existed in AF severity
cale. High AF severity scale scores (indicating more symp-
oms of AF) at baseline (scores above the mean value 1
D) were associated with symptoms of AF and female sex.
All subscales of the MFI-20 were comparable between
oth groups at baseline (Table 3). High scores (scores above
he mean value 1 SD) on the MFI-20 subscales, indicat-
ng more symptoms of fatigue, were associated with symp-
oms of AF at baseline (general fatigue, physical fatigue,
educed activity, and reduced motivation), and female sex
SF-36 ScoreTable 2 SF-36 Score
SF-36 Subscale Strategy Baseline 12 Months End of
General health Lenient 59 (17) 58 (18) 59 (1
Strict 58 (18) 59 (18) 58 (1
Physical functioning Lenient 70 (22) 69 (23) 65 (2
Strict 64 (25) 68 (24)* 62 (2
Physical role limitation Lenient 64 (42) 62 (42) 69 (4
Strict 58 (42) 68 (40)* 60 (4
Bodily pain Lenient 84 (20) 84 (22) 81 (2
Strict 81 (22) 83 (21) 80 (2
Mental health Lenient 79 (17) 79 (16) 79 (1
Strict 81 (15) 81 (14) 81 (1
Social functioning Lenient 84 (20) 85 (18) 84 (2
Strict 82 (21) 84 (21) 81 (2
Emotional role limitation Lenient 78 (36) 79 (36) 82 (3
Strict 78 (36) 81 (14) 81 (3
Vitality Lenient 66 (20) 65 (18) 64 (2
Strict 64 (19) 64 (19) 63 (2
*p  0.05 compared with baseline score.
SF-36  Medical Outcomes Study 36-item Short-Form Health Survey.
MFI-20 ScoresTable 3 MFI-20 Scores
Factor Strategy Baseline 12 Months End of S
General fatigue Lenient 11 5 11 5 12
Strict 11 5 11 5 12
Physical fatigue Lenient 11 5 11 5 11
Strict 11 5 11 5 12
Reduced activity Lenient 11 5 10 4 11
Strict 11 5 11 4 11
Reduced motivation Lenient 10 4 9 4 10
Strict 10 4 9 4 10
Mental fatigue Lenient 8 4 8 4 9
Strict 7 4 8 4 8Values are expressed as mean  SD or %.
MFI-20  Multidimensional Fatigue Inventory–20.physical fatigue and reduced activity). There was also no
ifference in QOL, in any of the questionnaires used,
etween patients with a high baseline heart rate (100
eats/min) versus those with a normal baseline heart rate
data not shown).
hanges in QOL from baseline to end of study. In the
enient control group, no significant differences were found
etween baseline and 12 months’ follow-up in the SF-36.
owever, at study end, the subscales physical functioning
nd bodily pain significantly worsened compared with
aseline (Table 2). In the strict control group, at 12 months
f follow-up, physical functioning and role limitations due
o physical problems improved (Table 2). At 12 months of
ollow-up and at the end of study, no differences were
resent between the lenient and strict control groups in any
f the SF-36 subscales (Table 2). There were also no
ignificant correlations between heart rate at baseline, at the
nd of the dose-adjustment phase nor end of study, and the
F-36 subscales scores of baseline and study end, respec-
Relevant Improvement
From Baseline to End of Study (%)
Relevant Worsening
From Baseline to End of Study (%)
19 16
16 23
13 24
17 26
24 24
28 24
14 21
16 17
22 18
18 24
15 13
17 15
21 17
22 13
17 23
16 19
Relevant Improvement
From Baseline to End of Study (%)
Relevant Worsening
From Baseline to End of Study (%)
21 24
19 22
17 27
21 25
22 24
20 26
20 24
17 30
16 26
15 25Study
9)
9)
5)*
7)*
1)
4)
2)*
3)
8)
4)
1)
2)
3)
4)
1)
0)tudy
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Quality of Life in Permanent Atrial Fibrillation October 18, 2011:1795–803tively. There was also no relation with heart rate and
changes in QOL. Comparable percentages of patients
showed a relevant improvement or worsening from baseline
to end of study in the different subscales. All effect sizes
were 0.25, indicating small changes from baseline to end
of study.
There were no significant differences in AF severity scale
in either the lenient (6 [IQR: 3 to 11]) or the strict (6 [IQR:
3 to 11]) control group between baseline and end of study.
At the end of follow-up, the AF severity scale was compa-
rable between groups. At baseline and at end of study, no
correlation was found between heart rate and the AF
severity scale. The relevant changes in the AF severity scale
were comparable in the lenient (improvement 22%; wors-
ening 26%) and strict (improvement 26%; worsening 21%)
control groups. All effect sizes (i.e., measurement of the
magnitude of change over time) were 0, indicating no
changes from baseline to end of study.
Patient Characteristics Associated With a ReleImprovement or Worsening in SF-36 Scores fromTable 4 Pa ient Characteris ics AssociatedImprovement or Worsening in SF-36
Factor Subscale
Improvement in SF-36 General health N
Physical functioning
Physical role limitation A
L
S
Bodily pain A
L
Mental health
Social functioning A
A
Emotional role limitation A
Vitality
Worsening in SF-36 General health A
D
S
Physical functioning A
A
Physical role limitation A
A
Bodily pain A
Mental health A
F
L
M
Social functioning A
P
A
B
Emotional role limitation A
P
Vitality A
*Defined as syncope, sustained ventricular tachycardia, cardiac arre
cardioverter-defibrillator implantation.CI confidence interval; HF heart failure; LVEF left ventricular ejection
Short-Form Health Survey.From baseline to 12 months of follow-up and until study
end, there were no significant differences in either rate control
strategy in any of the MFI-20 subscales. There were also no
differences between the lenient and strict control groups during
total follow-up (Table 3). The MFI-20 subscales at baseline
and end of study were not correlated with heart rate at baseline,
at the end of the dose-adjustment phase, or at end of study. All
effect sizes were0.25, indicating small changes from baseline
o end of study.
eterminants of changes in QOL. We investigated
hether rate control strategy, baseline characteristics, and
ollow-up parameters were associated with relevant changes in
OL in each questionnaire and their subscales. The parame-
ers considered in this analysis were underlying disease, echo-
ardiographic parameters at baseline, change in left ventricular
jection fraction from baseline to end of study, symptoms,
eart rate at the end of the dose-adjustment phase, relevant
eart rate reduction of a high baseline heart rate (100
eline to End of Studya R levant
res from Baseline to End of Study
rminants of Change in
Quality of Life OR (95% CI) p Value
ptom at end of study 1.7 (1.0–3.0) 0.049
— — —
ptom at baseline 2.0 (1.2–3.4) 0.013
er 10% 1.3 (1.0–1.7) 0.021
per mm 0.9 (0.8–1.0) 0.043
ptom at baseline 2.2 (1.2–3.9) 0.010
er 10% 1.3 (1.0–1.8) 0.032
— — —
ptom at baseline 2.2 (1.2–4.0) 0.007
r 10 yrs 0.6 (0.4–0.9) 0.007
ptom at baseline 2.7 (1.5–4.6) 0.001
— — —
ptom at end of study 2.5 (1.4–4.3) 0.002
s mellitus 2.4 (1.0–5.0) 0.041
per mm 1.1 (1.0–1.3) 0.034
ptom at end of study 2.0 (1.2–3.2) 0.007
r 10 yrs 1.7 (1.2–2.5) 0.003
ptom at end of study 1.9 (1.1–3.1) 0.017
r 10 yrs 1.6 (1.1–2.3) 0.016
ptom at end of study 2.0 (1.2–3.3) 0.007
ptom at end of study 2.1 (1.2–3.6) 0.011
2.3 (1.3–4.2) 0.004
er 10% 0.7 (0.5–0.9) 0.004
leeding during study 5.0 (1.7–23.7) 0.041
ptom at end of study 2.0 (1.1–3.5) 0.023
s hospitalization for HF 2.7 (1.1–6.2) 0.025
mic event during study* 4.4 (1.2–15.8) 0.024
ocker use 2.6 (1.4–4.6) 0.002
ptom at end of study 1.9 (1.1–3.3) 0.027
s hospitalization for HF 2.6 (1.1–5.9) 0.024
ptom at end of study 2.0 (1.2–3.2) 0.008
hreatening adverse effects of rate control drugs, and pacemaker orvantBasWi h
Sco
Dete
o sym
ny sym
VEF p
eptum
ny sym
VEF p
ny sym
ge pe
ny sym
ny sym
iabete
eptum
ny sym
ge pe
ny sym
ge pe
ny sym
ny sym
emale
VEF p
ajor b
ny sym
reviou
rrhyth
eta-bl
ny sym
reviou
ny sym
st, life-tfraction; OR odds ratio; SF-36 Medical Outcomes Study 36-item
t
p
e
i
s
a
t
S
e
f
b
a
I
s
d
(
W
s
p
a
h
a
p
r
t
a
i
q
D
T
s
t
r
i
A
i
w
t
f
o
Q
o
Q
Q
i
b
s
(
e
a
r
t
r
a
p
r
I
b
a
a
p
(
h
h
1801JACC Vol. 58, No. 17, 2011 Groenveld et al.
October 18, 2011:1795–803 Quality of Life in Permanent Atrial Fibrillationbeats/min in combination with20% reduction from baseline
o the end of the dose-adjustment phase), and occurrence of a
rimary endpoint and one of the composites of the primary
ndpoint (hospitalization for heart failure, stroke, major bleed-
ng, and arrhythmic events).
Symptoms at baseline, absence of symptoms at end of
tudy, higher left ventricular ejection fraction, lower age,
nd a thinner septum were determinants of improvement of
he SF-36 (Table 4). Worsening of the subscales of the
F-36 were associated with the presence of symptoms at
nd of study, higher age, diabetes mellitus, thicker septum,
emale sex, lower left ventricular ejection fraction, beta-
locker use, hospitalization for heart failure, major bleeding,
nd an arrhythmic event during the study (Table 4).
mprovements in the AF severity scale were associated with
ymptoms at baseline (odds ratio [OR]: 4.1 [95% confi-
ence interval (CI): 2.2 to 7.4], p  0.001) and lower age
per 10-year OR: 0.7 [95% CI: 0.5 to 0.9], p  0.019).
orsening in the AF severity scale were associated with
ymptoms at end of study (OR: 3.1 [95% CI: 1.8 to 5.3],
 0.001). Worsening of the subscales of the MFI-20 were
ssociated with the presence of symptoms at end of study,
igher age, diabetes mellitus, thicker septum, female sex,
nd lower left ventricular ejection fraction (Table 5). Im-
rovements and worsening were not associated with heart
ate at the end of the dose-adjustment phase or randomiza-
ion strategy in any of the questionnaires used. In addition,
relevant heart rate reduction was not associated with
mprovements or worsening of QOL in any of the study
uestionnaires.
iscussion
he present analysis of the RACE II study suggests that
tringency of rate control does not affect QOL during
Patient Characteristics Associated With a ReleImprovement or Worsening in MFI-20 From BaseTable 5 Pa ient Characteris ics Ass ciatedImprovement or Worsening in MFI-2
Factor Subscale
Improvement in MFI-20 General fatigue
Physical fatigue
Reduced activity
Reduced motivation
Mental fatigue L
Worsening in MFI-20 General fatigue A
A
Physical fatigue A
N
A
N
Reduced activity D
S
Reduced motivation A
Mental fatigue FCAD  coronary artery disease; MFI-20  Multidimensional Fatigue Inventorreatment of patients with permanent AF. Of note, heart
ate was not related to formal QOL measures, both at
nclusion and follow-up. In contrast, straightforward clinical
F symptoms was related to formal QOL measures, both at
nclusion as well as during follow-up. However, symptoms
ere not affected by stringency of rate control, and therefore
he type of rate control did not affect QOL. During
ollow-up, minor changes in QOL occurred, but stringency
f rate control again was not influential. Instead, changes in
OL were related to age, symptoms at baseline and at end
f study, severity of underlying disease, and female sex.
OL in permanent AF. Compared with healthy subjects,
OL is reduced in patients with AF (3,4). Previous studies
n patients with AF have shown that QOL is comparable
etween rhythm and rate control strategies (4,5), although
inus rhythm is associated with an improvement in QOL
4,6,7). There are, however, no prospective studies on the
ffect of stringency of rate control on QOL. In a post-hoc
nalysis of AFFIRM, no significant relation between heart
ate and QOL was found (22). A comparable subanalysis in
he rate control arm of the first RACE study also showed no
elation between achieved heart rate and QOL (23). We
lso did not observe, in any of the questionnaires used in the
resent analysis, a relation between heart rate and QOL, or
ate control strategy and QOL, at baseline or at study end.
n contrast, QOL was influenced by age, symptoms at
aseline and at end of study, severity of underlying disease,
nd female sex.
Why do heart rate and stringency of heart rate control not
ffect QOL in AF? One explanation from our data is that
atients with permanent AF may lack typical AF symptoms
24). In our study cohort, almost half of the patients did not
ave AF-related symptoms, and overall patients were not
ighly symptomatic (see following details). The lack of
to End of Studya Relevant
m Baseline to End of Study
inants of Change in
Quality of Life OR (95% CI) p Value
— — —
— — —
— — —
— — —
— — —
er 10% 0.8 (0.6–1.0) 0.033
ptom at end of study 2.5 (1.5–4.2) 0.001
r 10 yrs 1.4 (1.0–2.0) 0.045
ptom at end of study 2.2 (1.4–3.7) 0.002
ptoms at baseline 1.7 (1.0–2.8) 0.036
r 10 yrs 1.6 (1.1–2.3) 0.008
3.1 (1.6–6.3) 0.001
s mellitus 2.9 (1.3–6.4) 0.008
per mm 1.1 (1.0–1.2) 0.036
r 10 yrs 1.7 (1.2–2.4) 0.002
1.6 (1.0–2.6) 0.039vantli eWi h
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emaley-20; other abbreviations as in Table 4.
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control with respect to improving QOL, irrespective of
strategy. In addition, symptoms may be driven by underly-
ing heart disease rather than the arrhythmia itself. This
finding is reflected in the fact that dyspnea and fatigue were
far more frequent than typical AF-related palpitations.
Finally, controlling rate does not preclude patients from
being symptomatic due to ventricular irregularity and the
latter may not be affected by stringency of rate control.
However, our data do not rule out that strict rate control
may have a beneficial effect on AF symptoms and QOL in
highly symptomatic AF patients, and that, conversely, more
and higher dosages of rate control drugs may have nega-
tively affected QOL in the strict control group. This is
illustrated by the association between worsening of social
functioning and beta-blocker use, which may be caused by
more symptoms of fatigue and a reduction in exercise
capacity caused by beta-blockers (21).
Patients included in RACE II were not highly symptom-
atic. About 40% of the included patients did not experience
any symptoms of AF. This is also reflected in the scores on
the SF-36 and the MFI-20 questionnaire. However, scores
of both the SF-36 and the MFI-20 were less favorable
compared with the general population (15,25) but compa-
rable to the scores found in patients with cancer (26).
Patients with chronic fatigue and patients with moderate
heart failure, however, had less favorable scores on the
MFI-20 questionnaire compared with our patients (18,27).
The relatively low symptom burden is also reflected in the
scores on the AF severity scale in our study. A previous
study in patients with highly symptomatic paroxysmal AF
reported scores as high as 12 on the AF severity scale (19).
It is well known that patients with permanent AF have
symptoms less often compared with patients with paroxys-
mal AF (24,28). Furthermore, the type of symptoms is
different between patients with paroxysmal and permanent
AF. Palpitations are the main complaint in paroxysmal AF,
compared with dyspnea in patients with persistent or
permanent AF (28), which was also the case in our patient
group. Notwithstanding these factors, presence of symp-
toms was related to QOL as well as changes in QOL over
time, and the latter was not affected by stringency of rate
control. Obviously, in highly symptomatic patients with
uncontrolled heart rate well above 110 beats/min at rest, rate
control would significantly affect QOL. However, our study
did not focus on these highly symptomatic acute patients in
whom some sort of rate control is unavoidable. Instead, we
included patients with, on average, 2 to 3 months of AF
with or without rate control drugs who were relatively
stable. The present analysis suggests that type of rate control
does not matter in terms of improvement in QOL.
Sex importantly influenced QOL. In the general popu-
lation, women also showed a lower QOL (29). In addition,
previous AF trials showed lower QOL in women compared
with men with persistent AF (4,30,31) and with paroxysmal
AF (30). In the Euro Heart Survey on Atrial Fibrillation(32) and in a Canadian cohort (33), women also had lower
QOL. It is still unknown why women with AF have lower
QOL. Comparable observations are known from women
with a previous myocardial infarction (34). Because men are
often overrepresented in clinical trials, more data on women
are clearly warranted.
Study limitations. The outcome of this QOL analysis
cannot be generalized to all patients with AF because all of
these study patients had permanent AF and were not highly
symptomatic. A trial evaluating high and low heart rates in
AF would ideally bring all patients to the relevant heart rate
targets. Although the differences in achieved heart rates
between both groups were smaller than might have been
expected, strategies to achieve the heart rate targets were
completely different, which may have led to differences in
QOL between groups. Although the QOL questionnaires
we used are validated, it is possible that these questionnaires
were not sensitive enough to detect true changes in QOL.
Conclusions
In patients with permanent AF, QOL was not affected by
stringency of rate control. Instead, symptoms, female sex,
age, severity of underlying disease, and occurrence of end-
points were associated with worsening of QOL.
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